Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trial
Official title:
A Phase 1, Multi-center, Open-label, Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10, GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Status | Recruiting |
Enrollment | 78 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Male patients 19 years of age or older at the date of written informed consent. 2. Patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, documented by bone or soft tissue lesions. 3. Patients with castration-resistant prostate cancer with a blood testosterone level of less than 50 ng/dL at the screening visit. 4. patients with metastatic castration-resistant prostate cancer (mCRPC) who meet the following criteria (based on PCWG3.0 modified RECIST 1.1) 1) Prior taxane therapy for metastatic prostate cancer or confirmed refusal or inadequacy of such therapy 2) Patients who have received prior docetaxel and at least one of the following agents: abiraterone acetate or enzalutamide before or after docetaxel treatment 3) Patients with progression of prostate cancer during/after prior therapy, in the investigator's judgment, with either of the following, in the internal or external castration state 1. PSA progression defined as at least 2 PSA level increases (=1 week interval between each test) and a PSA level of =2 ng/mL at Screening 2. Advanced soft tissue disease as defined by RECIST 1.1 3. Progressive bone disease defined as =2 new lesions on bone scan (per PCWG3) 5. Patients who are on androgen deprivation therapy (ADT) of any kind (patients who have not undergone bilateral orchiectomy must begin internal castration therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or anti-androgenic agents, at least 4 weeks prior to Baseline and must continue for the entire duration of the study) Exclusion Criteria: 1. patient has an active autoimmune disease or is receiving systemic steroid therapy or in immunosuppressive status. 2. Patient has history of chemotherapy, radiation chemotherapy, biological therapy, immunotherapy, or radiation therapy within 4 weeks prior to the screening visit (In case of nitrosoureas or mitomycin, 6 weeks prior to the screening visit) |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
SL VAXiGEN |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-emergent adverse events (TEAEs) | Number of participants with treatment-emergent adverse events (TEAEs) | Baseline to 23 weeks | |
Primary | Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 | Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 | Baseline to 48 weeks | |
Secondary | PSA response rate | % patients with a reduction in PSA level from baseline by 50% or greater | Baseline to 48 weeks | |
Secondary | PSA progression free survival | The interval from the date of randomisation to the date of first evidence of PSA progression or death from any cause, whichever occurred first. | Baseline to 48 weeks | |
Secondary | Radiographic progression free survival | The interval from the date of disease progression on CT and/or Tc bone scan or death from any cause, whichever occurred first. | Baseline to 48 weeks | |
Secondary | Change of induced T-cell responses for SL-T10 vaccine | Vaccine-induced T-cell responses assessed by immunoassays in peripheral blood | Baseline to 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01977651 -
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
|
Phase 4 | |
Recruiting |
NCT04015622 -
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
|
Phase 2 | |
Recruiting |
NCT05983198 -
A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06134232 -
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
|
Phase 3 | |
Recruiting |
NCT06126731 -
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05806814 -
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05658003 -
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05670106 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
|
Phase 2 | |
Recruiting |
NCT04691804 -
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT03896984 -
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
|
||
Recruiting |
NCT06334432 -
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03074032 -
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
|
Phase 1 | |
Recruiting |
NCT05032040 -
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
|
Phase 2 | |
Completed |
NCT03071328 -
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
|
Early Phase 1 | |
Active, not recruiting |
NCT02649790 -
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
|
Phase 1/Phase 2 | |
Completed |
NCT03030885 -
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Terminated |
NCT03712930 -
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
|
Phase 2 | |
Recruiting |
NCT06241846 -
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
|
Phase 2 | |
Recruiting |
NCT03903835 -
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
|
Phase 3 |